专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

21. 发明申请

US20220073611A1 ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE 有权
公开(公告)号：US20220073611A1
公开(公告)日：2022-03-10
申请号：US17599399
申请日：2019-06-08
申请人： Lankenau Institute for Medical Research
发明人： Scott K. Dessain , Rashmi Sharma , Fetweh H. AL-SALEEM
IPC分类号： C07K16/28 , G01N33/564
摘要： A recombinant, synthetic or monoclonal human antibody or fragment thereof that binds to an N-methyl-D-aspartate Receptor (NMDAR) epitope, which antibody or fragment comprises at least one a heavy chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs. 1, 3, or 5; or at least one a light chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs: 2, 4, or 6. Assays for diagnosis of ANRE employ these NMDAR-binding antibodies, constructs, or epitope binding fragments. In one embodiment, multiple of the NMDAR-binding antibodies or fragments are used as controls because they bind non-overlapping target sequences on the NMDAR ATD.

22. 发明申请

US20210040230A1 Methods and Compositions for the Treatment of Autoimmune and Inflammatory Diseases 有权
公开(公告)号：US20210040230A1
公开(公告)日：2021-02-11
申请号：US17011852
申请日：2020-09-03
申请人： Lankenau Institute for Medical Research
发明人： Lisa Laury-Kleintop , Laura Mandik-Nayak , George C. Prendergast , James Duhadaway
IPC分类号： C07K16/40 , C07K14/00 , C07K7/06 , A61K39/395 , C07K7/08 , A61K45/06 , A61K39/00
摘要： Compositions and methods for the treatment of autoimmune and inflammatory diseases are disclosed.

23. 发明授权

US09446007B2 Methods for maintaining or improving health, well-being and/or a physiological function in a subject 有权
标题翻译：用于维持或改善受试者的健康，福祉和/或生理功能的方法
公开(公告)号：US09446007B2
公开(公告)日：2016-09-20
申请号：US14673259
申请日：2015-03-30
申请人： DYNAMIS THERAPEUTICS, INC.
发明人： Annette Tobia , Arturo Bravo Nuevo , Lisa Laury-Kleintop
IPC分类号： A01N57/00 , A61K31/66 , A61K38/00 , A61P3/06 , A61K31/133 , A61K31/155
CPC分类号： A61K31/133 , A61K9/0053 , A61K31/155 , A61K45/06 , A61K2300/00
摘要： The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.
摘要翻译：本发明涉及一种治疗或预防受试者状况的方法，包括向受试者施用包含葡甲胺或其盐的可接受的组合物。本发明还涉及一种改善受试者的生理功能的方法，包括向受试者施用包含葡甲胺或其盐的可接受的组合物。

24. 发明授权

US09339516B2 Compositions and methods for the prevention of esophageal cancer 有权
标题翻译：预防食管癌的组成和方法
公开(公告)号：US09339516B2
公开(公告)日：2016-05-17
申请号：US14114236
申请日：2012-05-07
申请人： James M. Mullin , Jonathan Raines
发明人： James M. Mullin , Jonathan Raines
IPC分类号： A61K33/30 , A61K31/315 , A61K9/20
CPC分类号： A61K33/30 , A61K31/315
摘要： Methods of inhibiting Barrett's esophagus and/or adenocarcinoma in a subject are provided. In a particular embodiment, the method comprises administering at least one composition comprising at least one zinc compound and at least one pharmaceutically acceptable carrier to the esophagus of the subject. The zinc may be a pharmaceutically acceptable salt of zinc, such as zinc gluconate. The zinc may be administered, for example, orally, topically, or by an implantable medical device. In a particular embodiment, the methods further comprise administering at least one analgesic, anesthetic, or other therapeutic agent or therapy for the treatment of Barrett's esophagus. The method may further comprise monitoring the progression of Barrett's esophagus in the subject.
摘要翻译：提供了抑制受试者中Barrett食管和/或腺癌的方法。在一个具体实施方案中，所述方法包括向受试者的食道施用至少一种包含至少一种锌化合物和至少一种药学上可接受的载体的组合物。锌可以是药学上可接受的锌盐，例如葡萄糖酸锌。锌可以例如口服，局部施用或通过可植入医疗装置施用。在一个具体实施方案中，所述方法还包括施用至少一种止痛剂，麻醉剂或其它治疗剂或治疗用于治疗巴雷特氏食管。该方法还可以包括监测受试者中Barrett食管的进展。

25. 发明授权

US08586636B2 Disulfide chemotherapeutic agents and methods of use thereof 有权
标题翻译：二硫化物治疗剂及其使用方法
公开(公告)号：US08586636B2
公开(公告)日：2013-11-19
申请号：US12743682
申请日：2008-11-19
申请人： Iraimoudi S. Ayene , George C. Prendergast
发明人： Iraimoudi S. Ayene , George C. Prendergast
IPC分类号： A61K31/105
CPC分类号： A61K33/24 , A61K9/0019 , A61K31/10 , A61K31/194 , A61K31/198 , A61K31/7048 , A61K45/06 , A61K2300/00
摘要： Compositions and methods for the treatment of cancer are provided.
摘要翻译：提供了治疗癌症的组合物和方法。

26. 发明授权

US08383613B2 Methods for the treatment of cancer 有权
标题翻译：治疗癌症的方法
公开(公告)号：US08383613B2
公开(公告)日：2013-02-26
申请号：US13186848
申请日：2011-07-20
申请人： George C. Prendergast , Alexander J. Muller , James B. DuHadaway , William Malachowski
发明人： George C. Prendergast , Alexander J. Muller , James B. DuHadaway , William Malachowski
IPC分类号： A61K31/33
CPC分类号： C07D403/06 , A61K31/353 , A61K31/405 , A61K31/4745 , A61K38/04 , A61K45/06 , C07D209/14 , C07D403/12 , C07D403/14 , C07D471/04 , C07D513/04 , C07D517/04 , A61K2300/00
摘要： Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.
摘要翻译：公开了用于治疗恶性和慢性病毒感染的组合物和方法。

27. 发明授权

US08058416B2 Nucleic acid molecules encoding indoleamine 2,3-dioxygenase-2 有权
标题翻译：编码吲哚胺2,3-双加氧酶-2的核酸分子
公开(公告)号：US08058416B2
公开(公告)日：2011-11-15
申请号：US12273296
申请日：2008-11-18
申请人： George C. Prendergast , Richard Metz
发明人： George C. Prendergast , Richard Metz
IPC分类号： C07H21/02 , C07H21/04
CPC分类号： C12N9/0069 , A01K67/0276 , C07K2319/21 , C07K2319/40 , C12N2830/006 , C12Q1/26
摘要： The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.
摘要翻译：提供吲哚胺2,3-二加氧酶-2（IDO2）的核苷酸和氨基酸序列及其使用方法。

28. 发明公开

US20240191207A1 METHODS AND COMPOSITIONS FOR INDUCIBLE EXTRACELLULAR MEMBRANE CAPTURE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS 审中-公开
公开(公告)号：US20240191207A1
公开(公告)日：2024-06-13
申请号：US18443701
申请日：2024-02-16
申请人： Lankenau Institute for Medical Research
发明人： Scott K. Dessain , Rama Devudu Puligedda
IPC分类号： C12N5/16 , C07K16/10 , C12N15/10 , G01N33/569
CPC分类号： C12N5/163 , C07K16/10 , C12N15/1034 , G01N33/56966 , C07K2317/14 , C07K2317/21
摘要： Compositions and methods are provided for making and using a cell having expressed on its outer plasma membrane surface an Anchor designed to form a first complex with a selected Linker. The Linker is designed to form a second complex with a target protein that is not recognized by the Anchor. These cells can be primary cells or immortalized cells, and can function as fusion partners to create hybridoma cells.

29. 发明授权

US11992532B2 Hydrogels and methods of using the same 有权
公开(公告)号：US11992532B2
公开(公告)日：2024-05-28
申请号：US17437579
申请日：2020-03-11
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , LANKENAU INSTITUTE FOR MEDICAL RESEARCH
发明人： Phillip B. Messersmith , Jing Cheng , Ellen Heber-Katz
IPC分类号： A61K47/69 , A61K47/60
CPC分类号： A61K47/6903 , A61K47/60
摘要： Disclosed herein are PEG-DPCA conjugates having multiple hydrophobic DPCA groups at one or both terminal ends of a PEG compound and compositions thereof and methods of using thereof for tissue regeneration and/or cellular repair (e.g., wound healing).

30. 发明授权

US11946074B2 Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas 有权
公开(公告)号：US11946074B2
公开(公告)日：2024-04-02
申请号：US16495552
申请日：2018-03-23
申请人： Lankenau Institute for Medical Research
发明人： Scott K. Dessain , Rama Devudu Puligedda
IPC分类号： C12N5/16 , C07K16/10 , C12N15/10 , G01N33/569
CPC分类号： C12N5/163 , C07K16/10 , C12N15/1034 , G01N33/56966 , C07K2317/14 , C07K2317/21
摘要： Compositions and methods are provided for making and using a cell having expressed on its outer plasma membrane surface an Anchor designed to form a first complex with a selected Linker. The Linker is designed to form a second complex with in a target protein that is not recognized by the Anchor. These cells can be primary cells or immortalized cells, they function as fusion partners to create hybridoma cells. The cells can be designed to bind a secreted targeted protein, e.g., a secreted antibody, to the cell surface via an immune complex formed by the Anchor-Linker and permit the identification of the existence, antigen specificity, and antigen binding affinity, titer, amount, or biological activity of the target protein. In certain embodiments, the Linker is of a species heterologous to the species of the Anchor; and the target protein is of a species heterologous to the Linker and to the Anchor.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式